Simian Adenoviruses As Vaccine Vectors

Overview

Journal Future Virol

Specialty Microbiology

Date 2018 Mar 13

PMID 29527232

Citations 49

Authors

Susan J Morris

Sarah Sebastian

Alexandra J Spencer

Sarah C Gilbert

Affiliations

Soon will be listed here.

Abstract

Replication incompetent human adenovirus serotype 5 (HAdV-C5) has been extensively used as a delivery vehicle for gene therapy proteins and infectious disease antigens. These vectors infect replicating and nonreplicating cells, have a broad tissue tropism, elicit high immune responses and are easily purified to high titers. However, the utility of HAdV-C5 vectors as potential vaccines is limited due to pre-existing immunity within the human population that significantly reduces the immunogenicity of HAdV-C5 vaccines. In recent years, adenovirus vaccine development has focused on simian-derived adenoviral vectors, which have the desirable vector characteristics of HAdV-C5 but with negligible seroprevalence in the human population. Here, we discuss recent advances in simian adenovirus vaccine vector development and evaluate current research specifically focusing on clinical trial data.

Citing Articles

Aerosol immunization with influenza matrix, nucleoprotein, or both prevents lung disease in pig.

Vatzia E, Paudyal B, Dema B, Carr B, Sedaghat-Rostami E, Gubbins S NPJ Vaccines. 2024; 9(1):188.

PMID: 39397062 PMC: 11471855. DOI: 10.1038/s41541-024-00989-8.

Viral vector- and virus-like particle-based vaccines against infectious diseases: A minireview.

Henriquez R, Munoz-Barroso I Heliyon. 2024; 10(15):e34927.

PMID: 39144987 PMC: 11320483. DOI: 10.1016/j.heliyon.2024.e34927.

The Immune System-A Double-Edged Sword for Adenovirus-Based Therapies.

Wallace R, Bliss C, Parker A Viruses. 2024; 16(6).

PMID: 38932265 PMC: 11209478. DOI: 10.3390/v16060973.

Recent SARS-CoV-2 Outlook and Implications in a COVID-19 Vaccination Era.

Ehianeta T, Mzee S, Adebisi M, Ehianeta O Infect Microbes Dis. 2024; 3(3):125-133.

PMID: 38630122 PMC: 8454280. DOI: 10.1097/IM9.0000000000000072.

Triple tandem trimer immunogens for HIV-1 and influenza nucleic acid-based vaccines.

Moral-Sanchez I, Wee E, Xian Y, Lee W, Allen J, Torrents de la Pena A NPJ Vaccines. 2024; 9(1):74.

PMID: 38582771 PMC: 10998906. DOI: 10.1038/s41541-024-00862-8.

References

Cappuccini F, Stribbling S, Pollock E, Hill A, Redchenko I . Immunogenicity and efficacy of the novel cancer vaccine based on simian adenovirus and MVA vectors alone and in combination with PD-1 mAb in a mouse model of prostate cancer. Cancer Immunol Immunother. 2016; 65(6):701-13. PMC: 4880633. DOI: 10.1007/s00262-016-1831-8. View

Krause A, Whu W, Qiu J, Wafadari D, Hackett N, Sharma A . RGD capsid modification enhances mucosal protective immunity of a non-human primate adenovirus vector expressing Pseudomonas aeruginosa OprF. Clin Exp Immunol. 2013; 173(2):230-41. PMC: 3722923. DOI: 10.1111/cei.12101. View

Green C, Scarselli E, Sande C, Thompson A, de Lara C, Taylor K . Chimpanzee adenovirus- and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults. Sci Transl Med. 2015; 7(300):300ra126. PMC: 4669850. DOI: 10.1126/scitranslmed.aac5745. View

Blanchette P, Kindsmuller K, Groitl P, Dallaire F, Speiseder T, Branton P . Control of mRNA export by adenovirus E4orf6 and E1B55K proteins during productive infection requires E4orf6 ubiquitin ligase activity. J Virol. 2008; 82(6):2642-51. PMC: 2258987. DOI: 10.1128/JVI.02309-07. View

Colloca S, Barnes E, Folgori A, Ammendola V, Capone S, Cirillo A . Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Sci Transl Med. 2012; 4(115):115ra2. PMC: 3627206. DOI: 10.1126/scitranslmed.3002925. View

Biswas S, Choudhary P, Elias S, Miura K, Milne K, de Cassan S . Assessment of humoral immune responses to blood-stage malaria antigens following ChAd63-MVA immunization, controlled human malaria infection and natural exposure. PLoS One. 2014; 9(9):e107903. PMC: 4177865. DOI: 10.1371/journal.pone.0107903. View

De Santis O, Audran R, Pothin E, Warpelin-Decrausaz L, Vallotton L, Wuerzner G . Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study. Lancet Infect Dis. 2016; 16(3):311-20. DOI: 10.1016/S1473-3099(15)00486-7. View

Zhou D, Cun A, Li Y, Xiang Z, Ertl H . A chimpanzee-origin adenovirus vector expressing the rabies virus glycoprotein as an oral vaccine against inhalation infection with rabies virus. Mol Ther. 2006; 14(5):662-72. DOI: 10.1016/j.ymthe.2006.03.027. View

Dobner T, Horikoshi N, Rubenwolf S, Shenk T . Blockage by adenovirus E4orf6 of transcriptional activation by the p53 tumor suppressor. Science. 1996; 272(5267):1470-3. DOI: 10.1126/science.272.5267.1470. View

10.

Antrobus R, Coughlan L, Berthoud T, Dicks M, Hill A, Lambe T . Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens. Mol Ther. 2013; 22(3):668-674. PMC: 3944330. DOI: 10.1038/mt.2013.284. View

11.

Kobinger G, Feldmann H, Zhi Y, Schumer G, Gao G, Feldmann F . Chimpanzee adenovirus vaccine protects against Zaire Ebola virus. Virology. 2005; 346(2):394-401. DOI: 10.1016/j.virol.2005.10.042. View

12.

Catanzaro A, Koup R, Roederer M, Bailer R, Enama M, Moodie Z . Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect Dis. 2006; 194(12):1638-49. PMC: 2428071. DOI: 10.1086/509258. View

13.

Sheehy S, Duncan C, Elias S, Biswas S, Collins K, OHara G . Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors. PLoS One. 2012; 7(2):e31208. PMC: 3283618. DOI: 10.1371/journal.pone.0031208. View

14.

OHara G, Duncan C, Ewer K, Collins K, Elias S, Halstead F . Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector. J Infect Dis. 2012; 205(5):772-81. PMC: 3274376. DOI: 10.1093/infdis/jir850. View

15.

Hayton E, Rose A, Ibrahimsa U, Del Sorbo M, Capone S, Crook A . Safety and tolerability of conserved region vaccines vectored by plasmid DNA, simian adenovirus and modified vaccinia virus ankara administered to human immunodeficiency virus type 1-uninfected adults in a randomized, single-blind phase I trial. PLoS One. 2014; 9(7):e101591. PMC: 4090156. DOI: 10.1371/journal.pone.0101591. View

16.

Weinberg D, Ketner G . Adenoviral early region 4 is required for efficient viral DNA replication and for late gene expression. J Virol. 1986; 57(3):833-8. PMC: 252812. DOI: 10.1128/JVI.57.3.833-838.1986. View

17.

Barnes E, Folgori A, Capone S, Swadling L, Aston S, Kurioka A . Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med. 2012; 4(115):115ra1. PMC: 3627207. DOI: 10.1126/scitranslmed.3003155. View

18.

Ledgerwood J, Sullivan N, Graham B . Chimpanzee Adenovirus Vector Ebola Vaccine--Preliminary Report. N Engl J Med. 2015; 373(8):776. DOI: 10.1056/NEJMc1505499. View

19.

Tatsis N, Tesema L, Robinson E, Giles-Davis W, McCoy K, Gao G . Chimpanzee-origin adenovirus vectors as vaccine carriers. Gene Ther. 2005; 13(5):421-9. DOI: 10.1038/sj.gt.3302675. View

20.

Tatsis N, Blejer A, Lasaro M, Hensley S, Cun A, Tesema L . A CD46-binding chimpanzee adenovirus vector as a vaccine carrier. Mol Ther. 2007; 15(3):608-17. DOI: 10.1038/sj.mt.6300078. View